scispace - formally typeset
Journal ArticleDOI

Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.

Reads0
Chats0
TLDR
It is demonstrated that the inactivation of VEGFR-3 by a novel blocking monoclonal antibody (mAb) suppresses tumor growth by inhibiting the neo-angiogenesis of tumor-bearing tissues and suggests that the VEGF-C/VEG FR-3 pathway may serve another candidate target for cancer therapy.
About
This article is published in Blood.The article was published on 2000-07-15. It has received 223 citations till now. The article focuses on the topics: Angiogenesis & Vascular endothelial growth factor B.

read more

Citations
More filters
Journal ArticleDOI

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.

TL;DR: It is demonstrated that lymphatics can be established in solid tumors and implicates VEGF family members in determining the route of metastatic spread and could be blocked with an antibody specific for V EGF-D.
Journal ArticleDOI

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

TL;DR: Multiple doses of rhuMAb VEGF were well tolerated, and pharmacokinetic studies indicate that doses of > or = 0.3 mg/kg have a half-life similar to that of other humanized antibodies.
Journal ArticleDOI

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

TL;DR: It is shown that a soluble form of VEGFR-3 is a potent inhibitor of Vascular endothelial growth factor (VEGF)-C and VEGF-D signaling, and when expressed in the skin of transgenic mice, it inhibits fetal lymphangiogenesis and induces a regression of already formed lymphatic vessels, though the blood vasculature remains normal.
References
More filters
Journal ArticleDOI

Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis

TL;DR: The work from the authors' laboratories reviewed herein was supported by grants from the National Cancer Institute.
Journal ArticleDOI

What is the evidence that tumors are angiogenesis dependent

TL;DR: Method of treating a wound or burn which comprises directly dressing its surface with non-woven fabric comprising staple fibers of spun, regenerated collagen substantially free of telopeptides is disclosed.
Journal ArticleDOI

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

TL;DR: It is reported that formation of blood vessels was abnormal, but not abolished, in heterozygous VEGF-deficient (VEGF+/-) embryos, generated by aggregation of embryonic stem (ES) cells with tetraploid embryos (T-ES)16,17, and even more impaired in homozygous D1-VEGF- deficient (VDGF-/-) T-ES embryos, resulting in death at mid-gestation.
Journal ArticleDOI

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.

TL;DR: The generation of mice deficient in Flk-1 by disruption of the gene using homologous recombination in embryonic stem (ES) cells is reported, indicating that FlK-1 is essential for yolk-sac blood-island formation and vasculogenesis in the mouse embryo.
Journal ArticleDOI

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

TL;DR: It is demonstrated that inhibition of the action of an angiogenic factor spontaneously produced by tumour cells may suppress tumour growth in vivo.
Related Papers (5)